Hansa Biopharma

Virtual Investor Event

Autoimmune Deep Dive
Guillain-Barré Syndrome 

Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), discussing unmet need and current treatment landscape for Guillain-Barré syndrome (GBS).

June 16, 14:00 CEST/8:00 AM ET

Register and attend
CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical appoints Göran Arvidson as CFO

27 Jan 2015, 08:00
Regulatory information
Hansa Medical AB strengthens its organization by recruiting Göran Arvidson as CFO of the company. Göran Arvidson will assume his position immediately.

Göran Arvidson, born 1960, has significant experience from the life science sector. He has been Vice President and CFO of Swedish Orphan Biovitrum AB (publ) and has held senior positions with Procordia AB and Pharmacia AB. He has a MBA from Stockholm School of Economics. Göran Arvidson owns no shares in Hansa Medical.

Files

For further information, please contact:
Hansa Medical AB
Fredrik Lindgren, President and CEO
Mobile: 46 705 61 61 77
E-mail: [email protected]
www.hansamedical.com

About Hansa Medical AB
Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory conditions. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.